Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hair loss gel enters human safety testing

NCT ID NCT06927960

First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 27 times

Summary

This early-stage trial tested the safety of a new topical gel called AH-001 in 64 healthy volunteers and men with male pattern baldness. Participants received either a single dose or daily doses for a week of the gel or a placebo. The study focused on side effects and how the drug moves through the body, not on hair regrowth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Altasciences Clinical Los Angeles, Inc.

    Los Angeles, California, 90630, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AH-001 topical gel

What this could lead to

If safe, this could lead to a new topical treatment for male pattern baldness that helps regrow hair.

What could go wrong

This is an early Phase 1 safety trial with only 64 people. It does not test if AH-001 actually works for hair loss, and side effects are unknown.

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.